What is the Cohance Lifesciences Ltd share price today?

The share price of NSE:COHANCE-EQ on 01 Oct 2026 (as of 15:03:19 IST) is ₹446.95.

What is the NSE:COHANCE-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:COHANCE-EQ 52 week high low range shows a high of ₹917.85 and a low of ₹266.7.

What is the Cohance Lifesciences Ltd market cap?

As on 01 Oct 2026, Cohance Lifesciences Ltd market cap is ₹169950000000.

What is the shareholding pattern of Cohance Lifesciences Ltd Stock?

The shareholding pattern of Cohance Lifesciences Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 57.49% Foreign Institutional Investors (FII): 6.5% Domestic Institutional Investors (DII): 1.88% Mutual Funds: 18.21% Retail & Others: 15.92% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Cohance Lifesciences Ltd?

The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd is 159.983, and the Price-to-Book (PB) ratio is 2.9669, as on 01 Oct 2026.

Cohance Lifesciences Share Price

440.35-6.70 (-1.50%)

-41.55% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Login to analyze with FIA

1 Day

-1.50%

1 Week

-8.52%

1 Month

-2.43%

3 Month

+2.54%

6 Month

-9.18%

YTD

-16.70%

1 Year

-41.55%

5 Year

-11.40%

10 Year

NA

Max

+174.36%

1D

1W

1M

3M

6M

YTD

1Y

5Y

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

438.50

436.85

427.50

416.20

391.05

266.70

High

453.15

481.30

493.05

505.00

760.80

About

Cohance Lifesciences is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

LAURUSLABSNSE

ZYDUSLIFENSE

DRREDDYNSE

CIPLANSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

COHANCENSE

LTP

1W Low

1W High

Market cap (₹)

1769.9+8.9 (0.51%)

1722

1855

4,24,202Cr

10064+400 (4.14%)

9621.50

10064

2,64,141Cr

4650+70 (1.53%)

4532

4675

1,74,402Cr

2323+79 (3.52%)

2206.10

2441.90

1,26,811Cr

1240.6+56.2 (4.75%)

1182

1254.20

1,23,685Cr

1368.3+23.3 (1.73%)

1336.70

1368.30

1,11,868Cr

1396.9+38.9 (2.86%)

1357

1396.90

1,11,650Cr

2475+5.7 (0.23%)

2457.90

2528

1,02,196Cr

1694.5+34.6 (2.08%)

1647.20

1697.40

96,951Cr

2015.9+26 (1.31%)

1974

2033.80

91,301Cr

440.35-41 (-8.52%)

436.85

481.30

17,089Cr

Cohance Lifesciences Share Price

440.35-6.70 (-1.50%)

-41.55% past 1 Year

Sign in to View

Open a free Demat account in minutes to start investing and screening .

Login Sign Up

Cohance Lifesciences Share Price

440.35-6.70 (-1.50%)

-41.55% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years18%

3 years19%

Last year-13%

Compounded Profit Growth

10 years-

5 years-13%

3 years-24%

Last year-69%

Stock Price CAGR

10 years-

5 years-2%

3 years-8%

1 year-41%

Return on Equity

10 years24%

5 years19%

3 years12%

Last year4%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	18%	19%	-13%
-	-13%	-24%	-69%
-	-2%	-8%	-41%
24%	19%	12%	4%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

LAURUSLABS

ZYDUSLIFE

DRREDDY

CIPLA

MANKIND

AUROPHARMA

LUPIN

COHANCE

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,769.9	₹424202 Cr	38.68	8.29	58.23	₹11479 Cr
10,064	₹264141 Cr	90.3	34.04	128.41	₹2568 Cr
4,650	₹174402 Cr	82.11	14.04	106.21	₹2163 Cr
2,323	₹126811 Cr	94.64	8.17	33.94	₹889 Cr
1,240.6	₹123685 Cr	27.41	9.42	62.53	₹5040 Cr
1,368.3	₹111868 Cr	39.95	11.08	59.2	₹4196 Cr
1,396.9	₹111650 Cr	38.54	10.86	52.6	₹3879 Cr
2,475	₹102196 Cr	45.57	17.23	76.26	₹1913 Cr
1,694.5	₹96951 Cr	26.11	17.95	96.84	₹3505 Cr
2,015.9	₹91301 Cr	16.51	30.95	154.35	₹5333 Cr
440.35	₹17089 Cr	160.87	-0.63	7.79	₹179 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

%

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Mar 2019
₹422 Cr	₹619 Cr	₹545 Cr	₹556 Cr	₹549 Cr	₹840 Cr	₹676 Cr	₹604 Cr	₹488 Cr	₹253 Cr	₹220 Cr	₹231 Cr	₹348 Cr	₹369 Cr	₹354 Cr	₹278 Cr	₹339 Cr	₹364 Cr	₹392 Cr	₹301 Cr	₹264 Cr	₹259 Cr	₹275 Cr	₹237 Cr	₹238 Cr	₹185 Cr	₹179 Cr	₹273 Cr	₹197 Cr	₹251 Cr
₹12 Cr	-₹2 Cr	₹6 Cr	₹16 Cr	₹14 Cr	₹12 Cr	₹22 Cr	₹16 Cr	₹19 Cr	₹17 Cr	₹14 Cr	₹20 Cr	₹11 Cr	₹11 Cr	₹13 Cr	₹11 Cr	₹11 Cr	₹17 Cr	₹65 Cr	₹5 Cr	₹6 Cr	₹3 Cr	₹5 Cr	₹36 L	₹6 Cr	₹5 Cr	₹5 Cr	₹5 Cr	₹2 Cr	₹41 L
₹435 Cr	₹617 Cr	₹551 Cr	₹571 Cr	₹563 Cr	₹852 Cr	₹698 Cr	₹620 Cr	₹507 Cr	₹270 Cr	₹234 Cr	₹251 Cr	₹358 Cr	₹381 Cr	₹367 Cr	₹289 Cr	₹350 Cr	₹381 Cr	₹456 Cr	₹306 Cr	₹270 Cr	₹262 Cr	₹280 Cr	₹238 Cr	₹244 Cr	₹190 Cr	₹184 Cr	₹278 Cr	₹200 Cr	₹251 Cr
₹471 Cr	₹572 Cr	₹496 Cr	₹479 Cr	₹482 Cr	₹665 Cr	₹482 Cr	₹436 Cr	₹394 Cr	₹197 Cr	₹167 Cr	₹144 Cr	₹192 Cr	₹210 Cr	₹219 Cr	₹191 Cr	₹199 Cr	₹217 Cr	₹216 Cr	₹188 Cr	₹158 Cr	₹174 Cr	₹146 Cr	₹147 Cr	₹134 Cr	₹115 Cr	₹105 Cr	₹153 Cr	₹100 Cr	₹135 Cr
₹13 Cr	₹97 Cr	₹102 Cr	₹137 Cr	₹126 Cr	₹241 Cr	₹259 Cr	₹222 Cr	₹145 Cr	₹90 Cr	₹80 Cr	₹118 Cr	₹178 Cr	₹183 Cr	₹160 Cr	₹111 Cr	₹162 Cr	₹174 Cr	₹251 Cr	₹127 Cr	₹120 Cr	₹97 Cr	₹143 Cr	₹98 Cr	₹117 Cr	₹82 Cr	₹84 Cr	₹131 Cr	₹105 Cr	₹122 Cr
₹7 Cr	₹9 Cr	₹9 Cr	₹9 Cr	₹10 Cr	₹10 Cr	₹11 Cr	₹10 Cr	₹10 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹2 Cr	₹5 Cr	₹1 Cr	₹29 L	₹1 Cr	₹2 Cr	₹74 L	₹1 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹7 Cr	₹8 Cr	₹4 Cr	₹4 Cr	₹2 Cr
-₹43 Cr	₹20 Cr	₹41 Cr	₹84 Cr	₹63 Cr	₹161 Cr	₹205 Cr	₹174 Cr	₹103 Cr	₹71 Cr	₹65 Cr	₹105 Cr	₹164 Cr	₹166 Cr	₹146 Cr	₹98 Cr	₹149 Cr	₹161 Cr	₹239 Cr	₹116 Cr	₹109 Cr	₹87 Cr	₹132 Cr	₹88 Cr	₹108 Cr	₹68 Cr	₹71 Cr	₹121 Cr	₹96 Cr	₹115 Cr
-₹45 Cr	₹8 Cr	₹29 Cr	₹66 Cr	₹46 Cr	₹117 Cr	₹153 Cr	₹138 Cr	₹75 Cr	₹53 Cr	₹47 Cr	₹80 Cr	₹121 Cr	₹124 Cr	₹108 Cr	₹72 Cr	₹108 Cr	₹92 Cr	₹160 Cr	₹80 Cr	₹81 Cr	₹64 Cr	₹98 Cr	₹65 Cr	₹81 Cr	₹53 Cr	₹52 Cr	₹89 Cr	₹75 Cr	₹75 Cr

Balance Sheet

Consolidated

Standalone

₹

%

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
—	—	—	—	—	—	—	—
₹38 Cr	₹25 Cr	₹25 Cr	₹25 Cr	₹25 Cr	₹25 Cr	₹13 Cr	₹0
₹18 Cr	₹82 Cr	₹2 Cr	₹0	₹0	₹0	₹0	₹13 Cr
₹3855 Cr	₹3542 Cr	₹2023 Cr	₹1710 Cr	₹1502 Cr	₹1155 Cr	₹832 Cr	₹578 Cr
₹3855 Cr	₹3542 Cr	₹2023 Cr	₹1710 Cr	₹1502 Cr	₹1155 Cr	₹832 Cr	₹578 Cr
₹3911 Cr	₹3649 Cr	₹2051 Cr	₹1735 Cr	₹1527 Cr	₹1181 Cr	₹845 Cr	₹590 Cr
₹123 Cr	₹144 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹50 Cr	₹130 Cr	₹0	₹5 Cr	₹28 Cr	₹36 Cr	₹0	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹91 Cr	₹0
₹95 Cr	₹102 Cr	₹65 Cr	₹58 Cr	₹54 Cr	₹31 Cr	₹28 Cr	₹29 Cr
₹901 Cr	₹750 Cr	₹21 Cr	₹70 L	₹46 L	₹74 L	₹51 L	₹0
₹40 L	₹26 L	₹0	₹8 Cr	₹9 Cr	₹7 Cr	₹8 Cr	₹6 Cr
₹1047 Cr	₹982 Cr	₹86 Cr	₹72 Cr	₹92 Cr	₹74 Cr	₹128 Cr	₹35 Cr
—	—	—	—	—	—	—	—
₹285 Cr	₹268 Cr	₹42 Cr	₹70 Cr	₹106 Cr	₹83 Cr	₹71 Cr	₹54 Cr
₹223 Cr	₹313 Cr	₹21 Cr	₹20 Cr	₹30 Cr	₹29 Cr	₹28 Cr	₹19 Cr
₹74 Cr	₹71 Cr	₹39 Cr	₹65 Cr	₹67 Cr	₹106 Cr	₹94 Cr	₹83 Cr
₹64 Cr	₹53 Cr	₹15 Cr	₹149 Cr	₹145 Cr	₹104 Cr	₹127 Cr	₹35 Cr
₹646 Cr	₹705 Cr	₹117 Cr	₹303 Cr	₹348 Cr	₹322 Cr	₹320 Cr	₹191 Cr
₹5727 Cr	₹5480 Cr	₹2254 Cr	₹2110 Cr	₹1967 Cr	₹1576 Cr	₹1292 Cr	₹816 Cr
₹53 Cr	₹58 Cr	₹18 Cr	₹6 Cr	₹6 Cr	₹6 Cr	₹10 Cr	₹11 Cr
₹170 Cr	₹258 Cr	₹39 Cr	₹69 Cr	₹96 Cr	₹141 Cr	₹185 Cr	₹83 Cr
—	—	—	—	—	—	—	—
₹4231 Cr	₹3788 Cr	₹929 Cr	₹876 Cr	₹694 Cr	₹570 Cr	₹457 Cr	₹347 Cr
₹862 Cr	₹681 Cr	₹260 Cr	₹212 Cr	₹160 Cr	₹128 Cr	₹100 Cr	₹77 Cr
₹3369 Cr	₹3107 Cr	₹670 Cr	₹663 Cr	₹534 Cr	₹441 Cr	₹357 Cr	₹271 Cr
₹173 Cr	₹332 Cr	₹179 Cr	₹165 Cr	₹30 Cr	₹96 Cr	₹102 Cr	₹111 Cr
₹262 Cr	₹145 Cr	₹131 Cr	₹117 Cr	₹117 Cr	₹361 Cr	₹307 Cr	₹7 L
₹262 Cr	₹145 Cr	₹131 Cr	₹117 Cr	₹117 Cr	₹361 Cr	₹307 Cr	₹7 L
₹71 Cr	₹86 Cr	₹22 Cr	₹9 Cr	₹13 Cr	₹11 Cr	₹15 Cr	₹11 Cr
₹19 Cr	₹13 Cr	₹0	₹0	₹7 Cr	₹16 L	₹20 L	₹22 L
₹3899 Cr	₹3687 Cr	₹1001 Cr	₹955 Cr	₹702 Cr	₹910 Cr	₹781 Cr	₹393 Cr
—	—	—	—	—	—	—	—
₹266 Cr	₹192 Cr	₹774 Cr	₹419 Cr	₹481 Cr	₹181 Cr	₹31 Cr	₹7 Cr
₹562 Cr	₹467 Cr	₹231 Cr	₹313 Cr	₹283 Cr	₹201 Cr	₹175 Cr	₹157 Cr
₹681 Cr	₹772 Cr	₹134 Cr	₹111 Cr	₹236 Cr	₹102 Cr	₹117 Cr	₹148 Cr
₹60 Cr	₹102 Cr	₹51 Cr	₹68 Cr	₹47 Cr	₹10 Cr	₹14 Cr	₹13 Cr
₹42 Cr	₹33 Cr	₹12 Cr	₹11 Cr	₹11 Cr	₹12 Cr	₹9 Cr	₹13 Cr
₹185 Cr	₹192 Cr	₹52 Cr	₹233 Cr	₹206 Cr	₹161 Cr	₹165 Cr	₹85 Cr
₹1796 Cr	₹1758 Cr	₹1253 Cr	₹1155 Cr	₹1265 Cr	₹667 Cr	₹511 Cr	₹423 Cr
₹1150 Cr	₹1053 Cr	₹1136 Cr	₹852 Cr	₹918 Cr	₹345 Cr	₹191 Cr	₹232 Cr
₹5727 Cr	₹5480 Cr	₹2254 Cr	₹2110 Cr	₹1967 Cr	₹1576 Cr	₹1292 Cr	₹816 Cr
₹102	₹140	₹80	₹68	₹60	₹46	₹66	₹0
₹102	₹140	₹80	₹68	₹60	₹46	₹33	₹0

Cash Flow

Consolidated

Standalone

₹

%

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
₹207 Cr	₹643 Cr	₹406 Cr	₹560 Cr	₹668 Cr	₹468 Cr	₹405 Cr	₹158 Cr
₹208 Cr	₹207 Cr	₹17 Cr	₹37 Cr	₹41 Cr	₹36 Cr	₹35 Cr	₹14 Cr
₹21 Cr	-₹73 L	₹72 Cr	₹6 Cr	-₹194 Cr	-₹12 Cr	₹54 Cr	-₹88 Cr
₹436 Cr	₹849 Cr	₹495 Cr	₹603 Cr	₹514 Cr	₹492 Cr	₹493 Cr	₹83 Cr
₹368 Cr	₹673 Cr	₹385 Cr	₹457 Cr	₹330 Cr	₹383 Cr	₹407 Cr	₹50 Cr
-₹255 Cr	-₹390 Cr	-₹362 Cr	-₹195 Cr	-₹136 Cr	-₹311 Cr	-₹413 Cr	-₹65 Cr
-₹165 Cr	-₹327 Cr	-₹40 Cr	-₹242 Cr	-₹156 Cr	-₹76 Cr	₹7 Cr	₹26 Cr
-₹51 Cr	-₹44 Cr	-₹18 Cr	₹20 Cr	₹37 Cr	-₹5 Cr	₹79 L	₹11 Cr
₹97 Cr	₹138 Cr	₹65 Cr	₹45 Cr	₹7 Cr	₹12 Cr	₹11 Cr	₹0
₹4 Cr	₹2 Cr	₹0	₹0	₹4,000	₹3,000	₹6,000	₹0
₹49 Cr	₹97 Cr	₹47 Cr	₹65 Cr	₹45 Cr	₹7 Cr	₹12 Cr	₹11 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Cohance Lifesciences Share Price

440.35-6.70 (-1.50%)

-41.55% past 1 Year

02 Jan 25+9D

Bid/Ask

Price

Greeks

Stradle

Custom

CALLS

Qty/ots

PUTS

Sign in to View

Open a free Demat account in minutes to start investing and screening .

Login Sign Up

Cohance Lifesciences Share Price

440.35-6.70 (-1.50%)

-41.55% past 1 Year

Shareholding summary

Promoters

57.48%

FII

7.71%

DII

1.93%

MF

16.93%

Others

15.95%

Promoters

FII

DII

MF

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
57.48%	57.49%	57.49%	57.49%	57.49%	66.41%
7.71%	6.50%	5.59%	6.01%	6.51%	7.23%
1.93%	1.88%	3.22%	4.21%	4.32%	2.50%
16.93%	18.21%	18.57%	17.36%	16.49%	8.90%
15.95%	15.92%	15.13%	14.93%	15.19%	14.96%

Bulk & block deals

Name

Jasti Family Trust

Jasub Property Holdings Llp

Jasti Family Trust

Jasub Property Holdings Llp

Jasti Family Trust

Jasub Property Holdings Llp

Jasti Family Trust

Bnp Paribas Financial Markets

Morgan Stanley Asia (Singapore) Pte.

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
23 Feb 2026	Sell	235.62 Cr	₹306	77 L	Block	2.012719	NSE
23 Feb 2026	Purchase	235.62 Cr	₹306	77 L	Block	2.012719	NSE
23 Feb 2026	Purchase	235.62 Cr	₹306	77 L	Bulk	2.012719	NSE
23 Feb 2026	Sell	235.62 Cr	₹306	77 L	Bulk	2.012719	NSE
18 Feb 2026	Purchase	216.30 Cr	₹309	70 L	Bulk	1.829744	NSE
18 Feb 2026	Sell	216.30 Cr	₹309	70 L	Bulk	1.829744	NSE
18 Feb 2026	Purchase	216.30 Cr	₹309	70 L	Block	1.829744	NSE
18 Feb 2026	Sell	216.30 Cr	₹309	70 L	Block	1.829744	NSE
23 Oct 2025	Purchase	10.02 Cr	₹890.75	1.12 L	Block	0.029405	BSE
23 Oct 2025	Sell	10.02 Cr	₹890.75	1.12 L	Block	0.029405	BSE

Insider trading & SAST

Client name

Dsp Trustee Pvt Ltd

Jusmiral Holdings Limited

Jasti Property & Equity Holdings Pvt Ltd & Others

Jasub Property Holdings Llp & Pacs

Jusmiral Holdings Ltd & Pacs

Jusmiral Holdings Limited

Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
25 Aug 2026	Other	Disposal	0.76	3.53	0	—	29 L	07 Aug 2026	Market	1,34,97,073	SAST	29(2)	—
09 Jul 2026	Promoter	Others	—	—	0	—	8.04 Cr	17 Jun 2026	Creation	8,04,34,990	SAST	Reg31	—
30 Jun 2026	Promoter	Others	—	—	0	—	9.24 Cr	16 Jun 2026	Release	0	SAST	Reg31	—
12 Mar 2026	Other	Disposal	2.01	6.36	0	—	77 L	23 Feb 2026	Inter-se Transfer	2,43,26,009	SAST	29(2)	—
09 Mar 2026	Other	Disposal	2.06	4.53	0	—	78.77 L	18 Feb 2026	Market	1,73,16,009	SAST	29(2)	—
09 Mar 2026	Other	Acquisition	1.83	1.83	0	—	70 L	18 Feb 2026	Inter-se Transfer	70,00,000	SAST	29(1)	—
01 Oct 2025	Promoter	Disposal	8.93	57.49	0	—	3.41 Cr	18 Sep 2025	Market	21,99,30,170	SAST	29(2)	—
23 Sep 2025	Promoter	Others	—	—	0	—	3.41 Cr	18 Sep 2025	Release	9,23,90,578	SAST	Reg31	—
19 Sep 2025	Promoter	Disposal	8.926016	24.15	3,093.81 Cr	₹906	3.41 Cr	18 Sep 2025	Market Sale	9,23,90,578	Insider Trading	—	Equity Shares
28 Aug 2025	Director	Disposal	0.156835	0.03	52.82 Cr	₹880.30	6 L	26 Aug 2025	Market Sale	1,13,259	Insider Trading	—	Equity Shares

Cohance Lifesciences Share Price

440.35-6.70 (-1.50%)

-41.55% past 1 Year

Cohance Lifesciences is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in

Corporate Actions

Date

Type

Details

No data available.

Company details

Registered office

215 Atrium, C Wing, 8th Floor, 819-821 Andheri, Kurla Road, Chakala Andheri (East), Chakala Midc Mumbai Maharashtra PIN: 400093 Tel No: 022-61539999 Fax No: NULL Email: [email protected] Internet: www.cohance.com

Registrars

Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com

Management

Umang Vohra, Chairman & Group CEO

Matangi Gowrishankar, Non Executive Independent Director

Vinod Rao, Non Executive Independent Director

K G Ananthakrishnan, Non Executive Independent Director

UB Pravin Rao, Non Executive Independent Director

Jai Shankar Krishnan, Non Executive Independent Director

Shweta Jalan, Non Executive Director

Pankaj Patwari, Non Executive Director

Vinod Padikkal, Non Executive Director

Sisir K Mishra, Company Secretary & Compliance Officer

Details